NYSE - Nasdaq Real Time Price USD

Emergent BioSolutions Inc. (EBS)

5.17 -0.19 (-3.51%)
As of 3:02 PM EDT. Market Open.
Loading Chart for EBS
DELL
  • Previous Close 5.36
  • Open 5.33
  • Bid 5.19 x 800
  • Ask 5.21 x 900
  • Day's Range 5.10 - 5.59
  • 52 Week Range 1.42 - 9.96
  • Volume 2,517,139
  • Avg. Volume 6,207,006
  • Market Cap (intraday) 271.022M
  • Beta (5Y Monthly) 1.24
  • PE Ratio (TTM) --
  • EPS (TTM) -10.97
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.00

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

www.emergentbiosolutions.com

1,600

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EBS

Performance Overview: EBS

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EBS
115.50%
S&P 500
9.97%

1-Year Return

EBS
43.66%
S&P 500
27.19%

3-Year Return

EBS
91.16%
S&P 500
27.55%

5-Year Return

EBS
88.46%
S&P 500
86.55%

Compare To: EBS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EBS

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    280.87M

  • Enterprise Value

    1.11B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.24

  • Price/Book (mrq)

    0.42

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -47.69%

  • Return on Assets (ttm)

    -0.38%

  • Return on Equity (ttm)

    -60.57%

  • Revenue (ttm)

    1.19B

  • Net Income Avi to Common (ttm)

    -565.3M

  • Diluted EPS (ttm)

    -10.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    78.5M

  • Total Debt/Equity (mrq)

    138.91%

  • Levered Free Cash Flow (ttm)

    133.66M

Research Analysis: EBS

Company Insights: EBS

Research Reports: EBS

People Also Watch